Form 4: CARGO Therapeutics Officer Sells Shares Post-Merger

Anup Radhakrishnan, Interim CEO of CARGO Therapeutics, disposed of all common stock and stock options following the company's acquisition by Concentra Biosciences.

Summary

• Reporting person Anup Radhakrishnan, Interim Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer of CARGO Therapeutics, Inc. (CRGX), reported changes in beneficial ownership.
• The changes are a result of the Agreement and Plan of Merger dated July 7, 2025, with Concentra Biosciences, LLC and Concentra Merger Sub VII, Inc.
• A tender offer for all outstanding shares of CARGO Therapeutics common stock was completed on August 18, 2025, at an offer price of $4.379 per share in cash plus one non-transferable contractual contingent value right (CVR).
• The merger became effective on August 19, 2025, with CARGO Therapeutics becoming a wholly owned subsidiary of Concentra Biosciences.
• On August 18, 2025, 57,345 shares of common stock were disposed of at $4.379 per share.
• On August 19, 2025, an additional 63,436 shares of common stock were disposed of at $4.379 per share, resulting in zero shares beneficially owned directly.
• On August 19, 2025, 14,679 stock options with an exercise price of $1.09 were disposed of. These options became fully vested and were converted into cash (the difference between the $4.379 cash amount and the $1.09 exercise price) and one CVR per underlying share.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger and tender offer, providing liquidity to shareholders and a clear valuation for the company's equity. While the company ceases to be independent, the transaction itself is a positive outcome for the acquired entity's shareholders, albeit with the uncertainty of CVRs.

Positives

• The reporting person received cash and Contingent Value Rights (CVRs) for their equity holdings, indicating a liquidity event.
• The merger provides a clear exit strategy and valuation for CARGO Therapeutics shareholders.

Negatives

• CARGO Therapeutics, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary.
• Shareholders no longer hold direct equity in CARGO Therapeutics, Inc.

Risks

• The value of the Contingent Value Rights (CVRs) is subject to future performance or milestones, introducing uncertainty regarding their ultimate value.
• Options with an exercise price equal to or greater than the Cash Amount ($4.379) were canceled for no consideration, potentially resulting in a loss for some option holders.

Future Outlook

The filing indicates the completion of an acquisition, meaning CARGO Therapeutics, Inc. will operate as a wholly-owned subsidiary of Concentra Biosciences, LLC. The future outlook for former CARGO Therapeutics shareholders who received CVRs depends on the terms and achievement of milestones associated with those CVRs.

Industry Context

This acquisition reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger entities acquire smaller, often clinical-stage, companies for their pipeline assets, technology, or market position. Such mergers aim to enhance portfolios and achieve synergies.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting insider transactions post-merger.
• The offer price of $4.379 per share plus a CVR is a specific valuation for CARGO Therapeutics. Without details on CARGO's pipeline, clinical stage, or market capitalization prior to the merger, a direct comparison to specific comparable companies or projects is not feasible from this filing alone.
• Contingent Value Rights (CVRs) are a common mechanism in biotech acquisitions to bridge valuation gaps or share future upside/risk, aligning with industry practices for certain types of M&A.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Former shareholders received cash and CVRs for their shares, providing liquidity and potential future upside from CVRs.
• Employees: Employees, particularly those with equity awards (RSUs, Options), had their awards vested and converted to cash and CVRs, providing a financial benefit. The long-term impact on employment depends on Concentra Biosciences' integration plans.
• Management: Key officers like Anup Radhakrishnan had their equity holdings converted, and their roles within the now-private entity will be redefined.

Next Steps

• CARGO Therapeutics, Inc. will operate as a wholly-owned subsidiary of Concentra Biosciences, LLC.
• The value of the Contingent Value Rights (CVRs) will depend on future events or milestones as defined in the CVR Agreement.

Key Dates

Recommendation

The company has been acquired, and its shares are no longer publicly traded. Shareholders who tendered their shares have already received the agreed-upon consideration (cash and CVRs). For any remaining shares not tendered, they would have been converted into the merger consideration at the effective time. Therefore, there is no longer a public market for CARGO Therapeutics, Inc. common stock, making a 'sell' recommendation appropriate for any remaining shares or for understanding the final disposition of the investment.

Keywords

CARGO Therapeutics, CRGX, Concentra Biosciences, Merger, Acquisition, Tender Offer, SEC Form 4, Insider Trading, Stock Disposition, Option Disposition, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals